Prevail Therapeutics to Present at Upcoming Conferences
SVB Leerink9th Annual Global Healthcare Conference on Thursday, February 27, 2020, fireside chat at 9:00 a.m. ETin New York, NY
Cowen and Company40th Annual Healthcare Conference on Tuesday, March 3, 2020, presentation at 12:00 p.m. ETin Boston, MA
The live webcast of each event will be available under “Events and Presentations” in the Investors & Media section of the company's website, www.prevailtherapeutics.com. The webcasts will be archived for 90 days following the events.
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with a GBA1 mutation (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutation (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr.
Source: Prevail Therapeutics